Clinical trials aren’t short on data. So why do critical decisions still feel harder than they should? Clinical trials are under a microscope. Regulators are asking tougher questions. Timelines are slipping. Sites are stretched. And recent guidance makes one thing clear: more data isn’t the answer. Better evidence is. Across the industry, programs aren’t stalling due to lack of effort or innovation. They stall when critical signals arrive fragmented, too late, or without enough confidence to act. What’s changing is the expectation. Decisions are expected to happen while trials are live—not after momentum is lost. For clinical and trial leaders, this translates to earlier insight, clearer signals, and the ability to course-correct before risk compounds. The teams making real progress aren’t adding noise. They’re building clarity into the process itself. Where do decision bottlenecks show up most in your trial workflows today? #ClinicalTrials #ClinicalDevelopment #TrialOperations #ClinicalResearch #LifeSciences #RealTimeInsights #RegulatoryAffairs Sanchit Mullick | Salim Afshar, MD, FACS | Tyler Weathers | Ramesh Sridharan | Chip Lynch | Alexis Isabelle | Vinitha S Rao
When evidence piles up, clinical decisions slow down. AI-driven clinical control towers enable continuous insight, near real-time monitoring, and earlier identification of issues across trials.